Virtu Financial’s Context Therapeutics CNTX Stock Holding History

Virtu Financial’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$61K	Sell	23,100 -5,821	-20%	-$13.6K	﹤0.01%	1256
2025 Q4	$43K	Buy	+28,921	New	+$33.8K	﹤0.01%	1323
2025 Q1	–	Sell	-11,638	Closed	-$12K	–	1454
2024 Q4	$12K	Buy	+11,638	New	+$20.1K	﹤0.01%	1366
2023 Q2	–	Sell	-41,191	Closed	-$23K	–	1591
2023 Q1	$23K	Sell	41,191 -16,264	-28%	-$12.3K	﹤0.01%	1220
2022 Q4	$38K	Buy	+57,455	New	+$61.9K	0.01%	1129
2022 Q3	–	Sell	-46,445	Closed	-$98K	–	1791
2022 Q2	$98K	Buy	+46,445	New	+$87K	0.01%	957
2022 Q1	–	Sell	-53,521	Closed	-$142K	–	1571
2021 Q4	$142K	Buy	+53,521	New	+$267K	0.01%	970

Other funds holding CNTX

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Virtu Financial's CNTX Position: Q1 2026 in Review

Virtu Financial reduced its Context Therapeutics (CNTX) stake by 20% in Q1 2026, selling an estimated $13.6K and leaving 23,100 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #1256.

Virtu Financial first reported a position in CNTX in Q4 2021 and has held it in 7 quarters since. The position peaked at $142K in Q4 2021. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

Virtu Financial held 23,100 shares of Context Therapeutics worth $61K as of Q1 2026.
Virtu Financial sold 5,821 Context Therapeutics shares in Q1 2026, an estimated $13.6K.
Context Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1256 holding.
Virtu Financial first reported a position in Context Therapeutics in Q4 2021 and has held it in 7 quarters since.
Virtu Financial's Context Therapeutics position peaked at $142K in Q4 2021.
59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.